Influences of sex and smoking habits on anticoagulant activity in low- molecular-weight heparin treatment of unstable coronary artery disease

American Heart Journal

Volumn 137, Issue 1, 1999, Pages 72-78

  Toss, Henrik ^a   Wallentin, Lars ^b   Siegbahn, Agneta ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING HABIT; STATISTICAL ANALYSIS;

EID: 0032905337     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70461-8     Document Type: Article

References (27)

1. 1. Bratt G, Törnbohm E, Widlund L, Lockner D. Low molecular weight heparins (Kabi 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration. Thromb Res 1986;42:613-20.
2. 2. Cosmi B, Fredenburgh J, Rischke J, Hirsh J, Young E, Weitz J. Effect of nonspecific binding to plasma proteins on the antithrombotic activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulphate. Circulation 1997;95:118-24.
3. 3. Frydman A, Bora L, Le Roux Y, Woler M, Chauliac M, Samama M. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-18.
4. 4. Boneu B, Buchanan M, Caranobe C, Gabaig A, Dupouy D, Sie P, et al. The disappearance of low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 1987;46:845-53.
5. 5. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987;58:932-5.
6. 6. Goudable C, Ton That H, Damani A, Durand D, Caranobe C, Sie P, et al. Low molecular weight heparin half life is prolonged in hemodialysed patients. Thromb Res 1986;43:1-5.
7. 7 Levine M, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relation between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.
8. 8. Alhenc-Gelas M, Guernic J-L, Vitoux J, Kher A, Aiach M, Fiessinger J. Adjusted versus fixed doses of the low-molecular-weight heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
9. 9. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand 1988;67:99-103.
10. 10. Leizorowicz A, Bara L, Samama M, Haugh M. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and hemorrhage. Haemostasis 1993;23(suppl 1):89-98.
11. 11. Koopman M, Prandoni P, Piovella F, Ockelford P, Brandjes D, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administrated in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7
12. 12. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
13. 13. Gurfinkel E, Manos E, Mejaíl R, Cerdá M, Duronto E, Garcia C, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
14. 14. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
15. 15. Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Laniado S, et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996;77:1145-8.
16. 16. The Thrombolysis In Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.
17. 17. Kontny F, Dale J, Abildgaard U, Pedersen T. Randomized trial of low molecular weight heparin (Dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in acute myocardial infarction (FRAMI) study. J Am Coll Cardiol 1997;30:962-9.
18. 18. Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
19. 19. Klein W, Buchwald A, Hillis, Monrad S, Sanz G, Turpie G, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997; 96:61-8.
20. 20. Granger C, Hirsch J, Califf R, Col J, White H, Betrui A, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation 1996; 93:870-8.
21. 21. Laslett L, White R. Predictors of the effect of heparin during cardiac catheterization. Cardiology 1995;86:380-3.
22. 22. Cipolle R, Siefert R, Neilan B, Zaske D, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.
23. 23. Handeland G, Abildgaard U. Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with Factor Xa and thrombin. Thromb Res 1984;35:627-36.
24. 24. SPSS 6.1 Syntax Reference Guide. SPSS Inc. 1994.
25. 25. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 1994;128:7-11.
26. 26. Merlini P, Bauer K, Ottrona L, Ardissiono D, Cattaneo M, Belli B, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.
27. 27. Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II study). Am J Cardiol;80:61E-3E.